{"id":21274,"date":"2026-06-15T23:38:00","date_gmt":"2026-06-15T21:38:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=b0499d1389c2629b811a8bd6e34b9ac6"},"modified":"2026-06-15T23:38:00","modified_gmt":"2026-06-15T21:38:00","slug":"saptalis-pharmaceuticals-launches-cyclosporine-ophthalmic-emulsion-0-05-and-expands-product-portfolio","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=21274","title":{"rendered":"Saptalis Pharmaceuticals Launches Cyclosporine Ophthalmic Emulsion 0.05% and Expands Product Portfolio"},"content":{"rendered":"<p>HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Saptalis Pharmaceuticals LLC today announced the commercial launch of <b>Cyclosporine Ophthalmic Emulsion 0.05%<\/b>, available in 30- and 60-count single-use vials, reinforcing its commitment to expanding access to high-quality treatments.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260615002347\/en\/2831385\/4\/SaptalisBWireLogo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260615002347\/en\/2831385\/22\/SaptalisBWireLogo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260615002347\/en\/2831385\/4\/SaptalisBWireLogo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260615002347\/en\/2831385\/21\/SaptalisBWireLogo.jpg\" \/><\/a><p>\nDry eye disease affects millions of patients worldwide. Cyclosporine Ophthalmic Emulsion 0.05% is a preservative-free, single-use formulation indicated to increase tear production and provides a convenient option for managing inflammation-associated tear deficiency.<\/p><p>\nIn addition to Cyclosporine Ophthalmic Emulsion, Saptalis also announced the approval and launch of several other products across multiple therapeutic categories:<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Tofacitinib Oral Solution, 1 mg\/mL (240 mL)<\/b>: Indicated for the treatment of autoimmune and inflammatory conditions, including rheumatoid arthritis and related disorders.<\/li>\n<li>\n<b>Hydroxyzine HCl Oral Solution, USP 10 mg\/5 mL (473 mL)<\/b>: Indicated for the symptomatic relief of anxiety and tension, and for the management of pruritus due to allergic conditions.<\/li>\n<li>\n<b>Chlorpromazine HCl Oral Concentrate, 30 mg\/mL (120 mL) and 100 mg\/mL (240 mL)<\/b>: Indicated for the treatment of schizophrenia, psychotic disorders, and for the control of severe nausea and vomiting.<\/li>\n<li>\n<b>Desoximetasone Cream, USP 0.05% and 0.25% (15 g and 60 g)<\/b>: Indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.<\/li>\n<li>\n<b>Fluocinonide Topical Solution, USP 0.05% (20 mL and 60 mL)<\/b>: Indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive scalp and skin conditions.<\/li>\n<\/ul><p>\n\u201cWith these launches, we continue to grow our generic business segment with U.S.-based manufacturing, while maintaining our primary focus on advancing our pipeline of innovative branded therapies addressing unmet medical needs,\u201d said Polireddy Dondeti, President and CEO of Saptalis Pharmaceuticals LLC.<\/p><p>\nThese additions strengthen Saptalis\u2019 portfolio of liquid and semi-solid dosage forms across ophthalmology, dermatology, psychiatry, and allergy-related therapeutic areas.<\/p><p>\nAll products are available by prescription and should be used under the supervision of a licensed healthcare provider.<\/p><p>\nFor full prescribing information, please visit <b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.saptalis.com&amp;esheet=54554102&amp;newsitemid=20260615002347&amp;lan=en-US&amp;anchor=www.saptalis.com&amp;index=1&amp;md5=89db1acea42d08055c735e903227ed35\" rel=\"nofollow\" shape=\"rect\">www.saptalis.com<\/a> <\/b>or contact <b><a  href=\"mailto:info@saptalis.com\" rel=\"nofollow\" shape=\"rect\">info@saptalis.com<\/a><\/b>.<\/p><p>\n<b>About Saptalis Pharmaceuticals<\/b><\/p><p>\nSaptalis Pharmaceuticals LLC is a specialty pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of generic and specialty brand products, with a focus on liquid and semi-solid dosage forms. Headquartered in Hauppauge, New York, Saptalis operates R&amp;D laboratories and a commercial manufacturing facility compliant with U.S. FDA cGMP standards.<\/p><p>\nWebsite: <b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.saptalis.com&amp;esheet=54554102&amp;newsitemid=20260615002347&amp;lan=en-US&amp;anchor=www.saptalis.com&amp;index=2&amp;md5=aad560f13de0b2da8dd9e81d29ac99d7\" rel=\"nofollow\" shape=\"rect\">www.saptalis.com<\/a><\/b><\/p><br\/> <b>Contacts<\/b> <br\/><p>\nPeruvemba Satish\n<br\/>Chief Financial Officer and Chief Commercial Officer\n<br\/>(631) 231-2751\n<br\/><a  href=\"mailto:info@saptalis.com\" rel=\"nofollow\" shape=\"rect\">info@saptalis.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>HAUPPAUGE, N.Y.&#8211;(BUSINESS WIRE)&#8211;Saptalis Pharmaceuticals LLC today announced the commercial launch of Cyclosporine Ophthalmic Emulsion 0.05%, available in 30- and 60-count single-use vials, reinforcing its commitment to expanding access to high-quali&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-21274","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/21274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21274"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/21274\/revisions"}],"predecessor-version":[{"id":21275,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/21274\/revisions\/21275"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}